Daily ShareChat: Ryman Healthcare
By Jenny Ruth
Ryman Healthcare is positioned to continue to benefit from its favourable business model, positive aging population fundamentals and strong management and operations, says Jason Familton, an analyst at First NZ Capital.
Familton has raised his forecast underlying profit for Ryman to $76.8 million for the year ending March 2012 from $75 million previously and his 2013 forecast to $84.8 million from $77.5 million previously.
Familton says the 2012 forecast implies earnings growth of 6.5%, below the medium-term target of 15%. “The main drivers for our slowing earnings growth in full-year 2012 are a flat housing market, new sales numbers being similarly to full-year 2011 and also resale margins declining slightly once again,” he says.
“Key risks to our forecasts remain changes in the general housing market and our house price assumptions. Other risks include the timing of developments being delayed and also execution risk around future land acquisitions.”
First NZ Capital is forecasting zero nominal house price inflation in the year ending March and then a return of close to long-term forecasts of 4.9% in full-year 2013.
Familton has also raised his valuation of the shares significantly from $2.47 to $3.14, partly reflecting changes in his underlying assumptions and Ryman's intention to step up its rate of development.
DISCLAIMER: To the extent that any of the content above constitutes advice, it is general advice that has been prepared without reference to investor’s objectives, financial situation or needs. Before acting on any advice, investors should consider the appropriateness of the advice and IRG recommend that investors should obtain appropriate financial, legal and taxation advice before making any financial investment decision. The report is based on information compiled from public information and private research. IRG have completed the report on a best endeavours basis and do not accept any liability of loss or damage. IRG suggest that clients use this as part of a decision making process and check key data before making any investment decisions.
Employees may have an interest in the securities discussed in this report.
Comments from our readers
No comments yet
Add your comment:
Ryman's dip a buying opportunity as Australian expansion looms, First NZ says
Ryman Healthcare Limited
Ryman says first-quarter trading ahead of year earlier, meets company target
Ryman boosts FY profit 13 percent as fee income jumps, portfolio value climbs
Ryman Healthcare first-half profit rises 15 percent
Ryman's 1st Qtr ahead of last year; 28th village in Petone
Ryman may seek ASX listing as shares reach record high, profits rise
Ryman shares reach record high as profits rise
Ryman posts record FY profit, beats guidance, on strong demand for units